Navigation Links
Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial
Date:5/11/2010

TSX Venture: QPT

EDMONTON, May 11 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

SL052 is an injectible, synthetic derivative of a small molecular weight compound called Hypocrellin, which is isolated from a parasitic fungus that grows on bamboo trees in China. In Quest's Phase I trial, SL052 is inactive in a patient's body until activated by laser light of specific wavelength. Upon light activation, oxygen radicals are formed which are known to be toxic to tumor cells. This method of treatment is known as photodynamic therapy or PDT.

"SL052 photodynamic therapy is a promising treatment modality for prostate cancer because of its potential to minimize collateral damage compared to conventional treatment approaches," said Dr. Madi R. Madiyalakan, Quest's Chief Executive Officer. "In preclinical trials, SL052 photodynamic therapy demonstrated an impressive safety and efficacy profile. In this Phase I trial, our goal is to establish a safe and tolerable dosing regime of SL052 photodynamic therapy and monitor the patients for signals of efficacy."

The clinical trial is being conducted in two stages. In the first stage, up to six patients undergoing radical prostatectomy will be enrolled to study the prostate specific localization of SL052 after intra-arterial delivery. In the second stage, the safety and preliminary efficacy of SL052 PDT treatment with light dose escalation will be studied in 12 patients with localized prostate cancer. The treatment response will be monitored by MRI, prostate biopsy and changes in baseline PSA, which is an antigen associated with prostate disease progression.

This multi-disciplinary clinical trial is being conducted at the Princess Margaret and Sunnybrook Hospitals in Toronto and the University of Alberta Hospital in Edmonton. Dr. John Trachtenberg and Dr. Laurence Klotz, both Professors of Surgery at the University of Toronto, and Dr. Ronald Moore, Professor of Surgery and Oncology at the University of Alberta are the lead investigators. Dr. Brian Wilson, Professor of Medical Biophysics at the University of Toronto and interventional radiologists Dr. Richard Owen, Dr. John Kachura and Dr. Robyn Pugash are the co-investigators.

The American Cancer Society estimates there will be more than 192,000 new cases of prostate cancer in the U.S. in 2009, making it the third most prevalent form of cancer behind lung and breast cancer.

About SL052

SL052 is a member of Quest PharmaTech's SonoLight Portfolio with the potential to reduce or eliminate the side effects associated with currently available cancer treatment modalities: surgery, chemotherapy and radiotherapy. While Quest's first clinical trial of the injectable form of SL052 will demonstrate its utility in photodynamic therapy, SL052 can also be adapted for use in sonodynamic as well as immunophotodynamic therapy for the treatment of prostate cancer. Its properties of activation with harmless physical agents (light and ultrasound), combined with its ability to generate cancer vaccines and stimulate an anti-cancer immune response provide an opportunity to develop SL052 in a broad-spectrum oncology arena targeting current unmet needs.

About Quest PharmaTech Inc.

Quest is a publicly traded, Alberta-based biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds and recently acquired monoclonal antibodies which target certain tumor antigens that are presented in a variety of cancers. Quest believes that by combining these antibodies with other cancer therapies such as chemotherapy, photodynamic therapy or radioimmuno therapy, it can potentially further complement and enhance treatment outcomes compared to antibody treatment alone.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


'/>"/>
SOURCE Quest PharmaTech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GenomeQuest & Thomson Reuters Host IP Seminar
2. Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study
3. GenomeQuest Hosts IP Workshop at Annual PIUG Conference in Baltimore
4. NIST racetrack ion trap is a contender in quantum computing quest
5. From 2-trillion-degree heat, researchers create new matter -- and new questions
6. GenomeQuest Hosting Seminar at ABRF Conference In Sacramento, CA
7. GenomeQuest Hosting Seminar at X Gen Congress In San Diego
8. Appeal of Lawsuit by Former Officer Dismissed; Request for Sanctions Granted
9. GenomeQuest Announces Boston Seminar: Sequence Data Management for Next Generation Sequencing
10. Catilin Contributes Key Extraction, Sequestration and Conversion Technologies to NAABB Consortium Developing Algal Biofuels
11. Quest Diagnostics Introduces Molecular Blood Test for Aiding Colorectal Cancer Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... commercially available malaria Plasmodium falciparum culture panels with standard concentrations of histidine rich ... are available in a range of concentrations from six different malaria strains, are ...
(Date:1/24/2017)... ... 2017 , ... The Foundation for Food and Agriculture Research, ... career nominees for the 2017 New Innovator in Food and Agriculture Research Award. ... in which one in nine people suffers from hunger. The Foundation for Food ...
(Date:1/24/2017)... CORAL GABLES, Fla. , Jan. 23, 2017 ... interdisciplinary network focused on scientific discovery and solutions, ... is creating the Frost Institutes for Science and ... technology, engineering, and mathematics (STEM) to help solve ... University of Miami President Julio Frenk ...
(Date:1/24/2017)... -- Today, the Fisher Center for Alzheimer,s Research Foundation is ... that could lead to the development of effective drugs ... groundbreaking research was conducted by the Fisher Center scientists ... Paul Greengard , in the quest to find ... scientists have linked a mutation that protects elderly people ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, Inc., ... in healthy volunteers of a novel calcium release-activated ... acute pancreatitis. Acute pancreatitis, sudden ... mild disorder, but can be very serious.  In severe ... sepsis, where extended hospital stays, time in the ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... biometric sensor technology, today announced the launch of ... sensor systems, the highly-accurate biometric sensor modules that ... biometric technology, experience and expertise. The two new ... designed specifically for hearables, and Benchmark BW2.0, a ...
(Date:12/20/2016)... 2016 The rising popularity of mobility ... is stoking significant interest in keyless access systems. ... low energy (BLE), biometrics and near-field communication (NFC) ... of wireless technologies in the automotive industry. This ... access systems opens the market to specialist companies ...
Breaking Biology News(10 mins):